4-phenylbutyric acid has been researched along with Parkinsonian Disorders in 3 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaneko, M | 3 |
| Nomura, Y | 2 |
| Kubota, K | 1 |
| Niinuma, Y | 1 |
| Okuma, Y | 2 |
| Sugai, M | 1 |
| Omura, T | 1 |
| Uesugi, M | 1 |
| Uehara, T | 1 |
| Hosoi, T | 1 |
| Inden, M | 1 |
| Kitamura, Y | 1 |
| Takeuchi, H | 1 |
| Yanagida, T | 1 |
| Takata, K | 1 |
| Kobayashi, Y | 1 |
| Taniguchi, T | 1 |
| Yoshimoto, K | 1 |
| Taira, T | 1 |
| Ariga, H | 1 |
| Shimohama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for 4-phenylbutyric acid and Parkinsonian Disorders
| Article | Year |
|---|---|
[Protective effects of HRD1 and 4-phenylbutyric acid against neuronal cell death].
Topics: Cell Death; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Neurons; Parkinsonia | 2004 |
Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Humans; Inclusion Bodies | 2006 |
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
Topics: alpha-Synuclein; Animals; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Endopl | 2007 |